Familial Adenomatous Polyposis (FAP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Familial Adenomatous Polyposis (FAP) Market Outlook
Thelansis’s “Familial Adenomatous
Polyposis (FAP) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Familial Adenomatous Polyposis
(FAP) treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Familial
Adenomatous Polyposis (FAP) Overview
Familial
adenomatous polyposis (FAP) is an autosomal-dominant disorder stemming from a
germline mutation in the adenomatous polyposis coli (APC) gene, situated on
chromosome 5q21. The hallmark of FAP is the emergence of numerous adenomatous
polyps along the gastrointestinal mucosa, notably in the colon, leading to a
high likelihood of colorectal cancer. FAP also presents extracolonic
manifestations such as osteomas, epidermal cysts, desmoid tumors, hamartomatous
polyps in the upper gastrointestinal tract, congenital hypertrophy of the
retinal pigmented epithelium (CHRPE), hepatoblastomas, and thyroid tumors.
Thyroid nodules afflict around 38% of FAP patients, with thyroid cancer often
diagnosed before FAP detection in a third of cases. Compared to sporadic
instances, FAP patients face a tenfold increase in thyroid cancer risk,
particularly papillary thyroid carcinoma (PTC) occurring at a frequency ranging
from 0.7% to 12%. Predominantly, follicular thyroid carcinoma (FTC) and
concurrent PTC and FTC are the primary thyroid malignancies observed in FAP,
though isolated cases of medullary thyroid cancer have also been documented.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment